We cannot continue to treat our elderly with such brutal disregard—Despite FDA warnings and CMS measures, antipsychotic use rises and electroshock continues on vulnerable seniors. https://t.co/7ALc40Ph8b
Biological psychiatry, a total failure. Thomas Insel, the director of the US National Institute of Mental Health from 2002 to 2015, said in an interview in 2017: “I spent 13 years at NIMH really pushing on the neuroscience and genetics of mental disorders, and when I look back on that I realize that while I think I succeeded at getting lots of really cool papers published by cool scientists at fairly large costs - I think $20 billion - I don’t think we moved the needle in reducing suicide, reducing hospitalizations, improving recovery for the tens of millions of people who have mental illness. I hold myself accountable for that.” https://t.co/YpqYhDZNLb
Until psychiatry’s unscientific billing bible—The Diagnostic and Statistical Manual of Mental Disorders (DSM)—is exposed for what it is, the mental health industry will keep profiting and misleading the public, as every psychiatric drug depends on a psychiatric diagnosis to fit their drug. The FDA requires a psychiatric diagnosis to approve and market the drug, yet it does not require proof that any psychiatric diagnosis is a verifiable medical condition. It all goes back to the DSM.
"The ostensible validity of the DSM is reinforced by psychiatry’s claim that mental illnesses are brain diseases—a claim supposedly based on recent discoveries in neuroscience, made possible by imaging techniques for diagnosis and pharmacological agents for treatment. This is not true. There are no objective diagnostic tests to confirm or disconfirm the diagnosis of depression; the diagnosis can and must be made solely on the basis of the patient’s appearance and behavior and the reports of others about his behavior.
"The chemical imbalance meshes very well with the idea that you simply give a drug which restores the balance. It’s a story. A mythology. A fable. Nobody has yet measured, demonstrated, or created a test to show that somebody has a chemical imbalance in their brain. Period."
—Dr. Thomas Szasz, Professor of Psychiatry
"I don’t just think antidepressants are overprescribed, I’m not convinced they’re useful at all. Antidepressants don’t rectify a chemical imbalance or any other biological process, as people were led to believe; they numb emotions"
"The question is, is this useful, and how harmful are they?" 👇
https://t.co/L4OybfIwGS
Sign The Petition to Demand NIH Research and FDA Warnings—If you have been harmed and are struggling with ongoing symptoms after taking an SSRI or SNRI antidepressant drug — such as sexual dysfunction, emotional numbness, social withdrawal, feeling detached from reality, brain fog, memory issues, worsening depression, severe anxiety, or severe inner restlessness — you may be experiencing an antidepressant injury. Sign the petition here https://t.co/yPo4gZpxJ2
Drug safety advocate Kim Witczak has launched a consumer petition calling on the FDA and NIH to investigate lasting antidepressant injuries. A 23-year drug safety veteran, she helped secure the FDA’s black box suicide warnings on antidepressants (2004 & 2006) and served 9 years as Consumer Representative on the FDA’s Psychopharmacologic Drugs Advisory Committee fighting to disclose drug risks to the public. https://t.co/yOUYvo8VDA
Despite the fact that the FDA has never required the ECT device to be proven as safe or effective... In 2018, the American Psychiatric Association (APA), not the type of organization to give up on a treatment simply because it had no proof of safety or efficacy, lobbied the FDA to expand its clearance for ECT to be used on children, stating, “Having access to a rapid and effective treatment such as ECT is especially meaningful in children and adolescents.”
And the FDA complied.
The fact is, manufacturers of ECT devices themselves have acknowledged serious risks. In submissions to the FDA, they listed cognitive adverse events, including prolonged seizures, brain damage (including structural injury and brain-cell injury), permanent brain damage, and death among the potential risks of the devices.
Historically the FDA only warns of psychiatric drug risks when enough public pressure forces them to do their job. This is what it took to finally get the FDA to issue suicidal ideation warnings on SSRIs 👇 Now it's the same playbook with Post SSRI sexual dysfunction-ignore it
The 2004 FDA "Black Box" Warnings on SSRI Antidepressants—A Brief, Vital History of Stonewalling
*In a 1991 FDA hearing before the FDA Psychopharmacologic Drugs Advisory Committee, dozens of victims spoke out about becoming suicidal only after being prescribed an SSRI antidepressant. The committee, many of whose members had heavy conflicts of interest with pharmaceutical companies, listened to hours of public testimony, including from academics citing SSRI antidepressant-induced suicidality, and then voted unanimously not to warn the public about this risk.
*It wasn’t until 2003, after the UK’s Medicines and Healthcare products Regulatory Agency (MHRA), led by researchers, including Dr. David Healy, confirmed the suicidal risks associated with antidepressants in children and adolescents, that the FDA was forced to review their own data.
*With the UK data making international headlines, the FDA was pressured to review its stance on the risks of SSRIs. The agency appointed Dr. Andrew Mosholder, an FDA epidemiologist, to analyze the data on suicidality linked to SSRIs.
*Mosholder, reviewed the SSRI Antidepressant clinical trial data submitted by pharmaceutical companies to the FDA for approval, reviewing years worth of data. His analysis not only identified an increased risk of suicidal ideation and behavior among children and adolescents taking SSRIs but also raised concerns about the drug's lack of efficacy.
*Mosholder’s findings indicated that most of the industry-sponsored clinical trials showed little to no benefit of SSRIs over placebo in treating pediatric depression. His review suggested that the risk-benefit ratio was unfavorable, given both the increased risk of suicidal behavior and the marginal or nonexistent clinical benefit.
*The FDA refused to allow Mosholder to release these findings. The only reason the data was ever made public (that the FDA was suppressing Mosholder from releasing his findings) is because this was leaked to the press:
* The Wall Street Journal broke the story in 2004 that Dr. Mosholder had confirmed SSRIs increased the risk of suicidality in children and adolescents. Their investigation revealed that the FDA had suppressed Mosholder’s findings, preventing him from publicly presenting the research.
*Following the revelations of FDA supression of data the WSJ and other press were exposing, the Subcommittee on Oversight & Investigations of the House Energy and Commerce Committee, called for hearings as to why the FDA would prohibit their own researcher from releasing his findings.
*During the hearing, in addition to being questioned about not releasing their own data to the public, the Chairman of the committee revealed that a whistleblower within the FDA provided internal FDA memos telling staffers not to comply with Congressional requests.
*In response, the Chairman threatened to send Capitol Police to the FDA’s offices to retrieve the documents if the agency did not comply with the committee's request.
*The FDA was accused of “stonewalling, slow rolling, and plain incompetence” during the hearing.
* A few months after being lambasted by Congress, the FDA finally held their second hearing on SSRI antidepressants causing suicidal ideation. Now with the eyes of the public and Congress upon them, and Mosholder's reveiews out in the open, the FDA finally issued black box warnings on antidepressants causing suicidal ideation.
*This was 13 years after the FDA was first presented with the facts from academics and public testimony (in 1991) providing ample evidence of the exact same claim.
“There are about 100 million youth in the US under 25... Of those, maybe 10% are on antidepressants. That’s 10 million youth whose sex lives could be up for grabs. Of those 10 million, maybe 20% have serious impediments in their sex lives. That’s 2 million young people possibly facing these issues.”
Shockingly, the US FDA has yet to require a specific warning about persistent post-SSRI sexual dysfunction (PSSD), revealing how much the US system has been captured by the drug companies it allegedly regulates.
~@AKECassels
Why Weren’t We Warned?
https://t.co/eQDPC7GzS7
Imagine a warm shower, your own bed, or a hug from your mother no longer bringing any comfort.
That’s how Lauren Friedman describes life with PSSD (post-SSRI sexual dysfunction). It goes well beyond the sexual side. What she lost is the ability to feel pleasure at all: from music, from touch, from warmth.
The part that stays with me is how few people are told about this before they start the medication. Back in 2019 the European Medicines Agency had SSRI labels updated to say sexual dysfunction can continue after people stop taking the drug. Most patients still have never heard the term.
Informed consent should cover the rare outcomes too, especially the ones that can last longer than the prescription. And nobody should quit their medication suddenly because of a clip. That’s a conversation to have with a doctor.
Largest For-Profit Psych Chain Settles Claims of Child Sexual Abuse at Virginia Hospital—UHS, the largest for-profit psychiatric chain long accused of prioritizing profits over safety (including a 2020 $122M DOJ settlement over unnecessary admissions, excessive stays, and improper restraints, plus repeated reports of patient abuse), reached a tentative settlement in lawsuits alleging its former Cumberland Hospital medical director, Dr. Daniel Davidow, sexually abused young patients by inappropriately touching their breasts and genitals during exams presented as routine medical checks.
The defendants deny liability. And yet, UHS has a major history of abuse: CCHR International has investigated UHS since ~2008 and filed 36,000 complaints against it to legislators, law enforcement, the FBI, Attorneys General, U.S. Attorneys, state licensing boards, and other state agencies, documenting a long history of patient abuse and related issues including assaults, restraints, and death, as well as rampant child abuse. See this link: https://t.co/hmnQZ6W3sP
Psychiatry’s Response: Attack and PR— “They won’t acknowledge their errors. They won’t back down. And they won’t stop, or even curtail, their destructive practices. They will not even seriously debate the issues. Instead, they’ve gone on the offensive. This offensive is two-pronged. Firstly, they attack those of us who speak out against them, and secondly, they are actively developing links to the media in the hopes that this will encourage reporters to portray them in a more favorable light.”
– Philip Hickey, Ph.D., psychologist from his 2014 article, Psychiatry’s Response: Attack and PR
The psychedelic bandwagon continues, despite recognition that the trials are flawed by blinding problems and lack of data on long-term safety. The idea of a new miracle cure is just too tempting. https://t.co/wyMchVGii0